Skip to main content

BioRadar adds three strategic advisors to advance biological early-warning platform

Author
18 November 2026

BioRadar PBC, a biological intelligence company building an early-warning platform designed to identify biological threats that targeted surveillance may miss, today announced that Dr. DJ Kleinbaum, Hon. Andy Weber and Dr. Daniel Widmaier have joined as strategic advisors.

"We've learned that detecting a biological threat is only half the problem. You also have to figure out what to do with that information and how you share it with leaders who can act on it" said Dr. Ashish Jha, Co-Founder and CEO of BioRadar. "DJ, Andy and Dan have each tackled challenges we’re working through, and I want their experience helping shape how we approach them."

Dr. DJ Kleinbaum – Laboratory Automation and Scale

Kleinbaum co-founded Emerald Cloud Lab, a pioneer in cloud lab technology and operations. His experience developing automated laboratory infrastructure brings expertise in scaling complex scientific operations while maintaining consistency, reproducibility, and quality.

"Most of the difficult work in biological sensing happens in the lab, long before anyone sees a dashboard," Kleinbaum said.

Hon. Andy Weber – Biodefense and Government Decision-Making

Weber served as Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense programs under President Barack Obama. A senior fellow at the Council on Strategic Risks, he brings three decades of national security experience. He will advise BioRadar on how biological intelligence can best meet the needs of government officials responsible for deterrence, preparedness and response.

"Pathogen early warning, rapid characterization and attribution are critical capabilities for deterring the development and use of prohibited biological weapons,” Weber said.

Dr. Dan Widmaier – Biotechnology Commercialization and Product Strategy

Widmaier co-founded Bolt Threads, where he helped build a biotechnology company that developed novel materials and brought them into commercial markets. His experience turning scientific research into commercial products will inform BioRadar's product strategy, usability and approach to bringing complex technology to market.

“Building the science is one challenge,” Widmaier said. “Figuring out how to turn it into a product people can use is another.”

The appointments follow BioRadar's announcement that Dr. David Relman of Stanford University and Dr. Kevin Esvelt of MIT will co-chair its Scientific Advisory Board. 

"We're asking each of our advisors to pressure-test a specific part of what we're building," said Dr. Nikki Romanik, co-founder and president of BioRadar. "We need them to challenge our assumptions and tell us what we're missing."

BioRadar is building its product for Dallas and has established a partnership with the Business Group on Health, which represents large employers on workforce health, benefits and healthcare policy.

About BioRadar

BioRadar is a biological intelligence company building an early-warning platform designed to identify biological activity and threats that targeted surveillance may miss. The platform combines broad biological sensing with clinical, syndromic, behavioral and public-health signals to establish location-specific baselines and flag meaningful changes. BioRadar was founded by Dr. Ashish Jha, former White House COVID-19 Response Coordinator, and Dr. Nikki Romanik, former Deputy Director and Chief of Staff of the White House Office of Pandemic Preparedness and Response Policy. More information is available at www.bioradar.com

Our Current Partners